Bioventus (NYSE:BVS) Hits New 1-Year High – Should You Buy?

Bioventus Inc. (NYSE:BVS) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $12.45 and last traded at $12.33, with a volume of 80940 shares changing hands. The stock had previously closed at $12.13.

Analyst Ratings Changes

BVS has been the topic of several analyst reports. Craig Hallum lifted their price objective on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, September 27th. Canaccord Genuity Group increased their price objective on shares of Bioventus from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th.

Bioventus Trading Up 1.5 %

The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -36.91 and a beta of 0.90. The company has a 50 day moving average of $10.32 and a 200 day moving average of $7.44. The company has a current ratio of 1.33, a quick ratio of 0.96 and a debt-to-equity ratio of 1.82.

Bioventus (NYSE:BVS) last released its earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.12. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. The firm had revenue of $151.22 million for the quarter, compared to analyst estimates of $137.70 million. During the same quarter in the prior year, the firm posted $0.14 earnings per share. As a group, research analysts anticipate that Bioventus Inc. will post 0.4 EPS for the current year.

Insider Activity

In other news, Director John A. Bartholdson acquired 25,500 shares of Bioventus stock in a transaction dated Monday, August 19th. The stock was bought at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the acquisition, the director now directly owns 6,939,357 shares in the company, valued at approximately $59,331,502.35. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director John A. Bartholdson purchased 25,500 shares of Bioventus stock in a transaction dated Monday, August 19th. The shares were bought at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the purchase, the director now owns 6,939,357 shares in the company, valued at approximately $59,331,502.35. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John A. Bartholdson bought 80,000 shares of the stock in a transaction on Friday, August 16th. The stock was purchased at an average cost of $8.55 per share, with a total value of $684,000.00. Following the acquisition, the director now owns 6,913,857 shares in the company, valued at approximately $59,113,477.35. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 32.90% of the company’s stock.

Institutional Investors Weigh In On Bioventus

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC purchased a new stake in shares of Bioventus in the third quarter valued at about $89,000. Mackenzie Financial Corp purchased a new position in shares of Bioventus in the second quarter valued at $77,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Bioventus in the second quarter worth about $87,000. Squarepoint Ops LLC boosted its holdings in Bioventus by 13.8% in the 2nd quarter. Squarepoint Ops LLC now owns 26,171 shares of the company’s stock valued at $150,000 after purchasing an additional 3,170 shares during the period. Finally, Marshall Wace LLP grew its position in Bioventus by 38.2% during the second quarter. Marshall Wace LLP now owns 332,291 shares of the company’s stock worth $1,911,000 after buying an additional 91,843 shares in the last quarter. 62.94% of the stock is owned by institutional investors.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.